74 results about "Tourette syndrome" patented technology

The present invention relates to methods for tuning treatment parameters in movement disorder therapy systems. The present invention further relates to a system for screening patients to determine viability as candidates for certain therapy modalities, such as deep brain stimulation (DBS). The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of tuning a therapy device using objective quantified movement disorder symptom data acquired by a movement disorder diagnostic device to determine the therapy setting or parameters to be provided to the subject via his or her therapy device. The present invention also provides treatment and tuning remotely, allowing for home monitoring of subjects.

The present invention relates to methods for remotely and intelligently tuning movement disorder of therapy systems. The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of remotely and intelligently or automatically tuning a therapy device using objective quantified movement disorder symptom data to determine the therapy setting or parameters to be transmitted and provided to the subject via his or her therapy device. The present invention also provides treatment and tuning intelligently, automatically and remotely, allowing for home monitoring of subjects.

The compounds are of the class of benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.

Pyridone-fused azabicyclic compounds of the formulaand their pharmaceutically acceptable salts and prodrugs, wherein R<1>, R<2 >and R<3 >are defined below, intermediates and methods for their preparation. Compositions and methods for using compounds of the formula I in the treatment of neurological and mental disorders related to a decrease in cholinergic function such as nicotine addiction, Huntington's Chorea, tardive dyskinesia, hyperkinesia, mania, dyslexia, schizophrenia, analgesia, attention deficit disorder (ADD), multi-infarct demetia, age related cognitive decline, epilepsy, neurological and mental disorders related to a decrease in cholinergic function, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), anxiety, obesity, Tourette's Syndrome and ulcerative colitis.

The compounds are of the class thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.

The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

The disclosure relates to the genome-wide identification of “rearrangement hotspots”. The disclosure also relates to a microarray chip system for use in detecting genomic rearrangements and a method of manufacturing a microarray chip system useful for detecting genomic rearrangements. The disclosure also relates to methods for detecting genomic rearrangements associated with genetic diseases. The disclosure further relates to methods for using copy number variants in chromosome 2 for detecting Tourette Syndrome.

The invention discloses a novel isoquinoline compound, and a synthetic method thereof as well as an application of the compound, which is used as an agonist or an inhibitor of dopamine receptors in the medicines for treating Parkinson's disease, schizophrenia, tristimania, Tourette syndrome, attention-deficit hyperkinetic syndrome, pituitary tumor, etc. The constitutional formula of the compound is as follows: wherein, R1 is the hydrocarbyl with a H, C1-C10 linear chain or fork chain, heteroatom-substituted hydrocarbyl and aromatic or fatty heterocycle or non-heterocycle substituted alkyl; X is carbonyl, methylene and imidogen, and is more than C-OH or more than C=; Y is carboxide, methylene and imidogen, and is more than C= or more than C=N-OH; the compound can have no D cycle or the D cycle can be various heterocycles of substituted five-membered fat and substituted six-membered fat or substituted five-membered aromatic and six-membered aromatic; n is 0-3.

Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

The present invention provides methods of identifying an increased risk of a dopamine dysregulation disorder in a human subject, including identifying increased risk of dementia, Parkinson's disease, Huntington's, epilepsy, mania, attention deficit disorder, anxiety, dyslexia, schizophrenia, depression, obsessive-compulsive disorders, alcoholism, obesity, addiction disorders, pathological gambling, attention deficit hyperactivity disorder, bipolar disorder, Tourette syndrome, substance dependence, sub stance abuse, substance overdose, and substance-related death.

The invention discloses a traditional Chinese medicine composition for treating childhood tourette syndrome and a preparation method thereof and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is mainly composed of following raw material medicines, by weight: 9-15 parts of stir-fried atractylodes macrocephala koidz, 9-15 parts of white peony roots, 9-15 parts of bombyx batryticatus, 9-15 parts of periostracum cicada, 9-15 parts of flemingia philippinensis, 9-15 parts of dioscorea nipponica makino, 3-6 parts of zaocys dhumnade, 6-9 parts of eriocaulon buergerianum and 3-6 parts of radix glycyrrhizae. According to the traditional Chinese medicine theories, the formula of the compatibility of the medicine is formed according to a monarch-minister assistant-guide principle. The stir-fried atractylodes macrocephala koidz has effects of tonifying qi and fortifying spleen and drying dampness and inducing diuresis; the white peony roots have effects of nourishing blood and softening liver and calming liver and relieving spasm; the bombyx batryticatus has effects of dispelling wind and relieving spasm and resolving phlegm and dissipating binds; the periostracum cicada has effects of extinguishing wind and relieving spasm; the flemingia philippinensis has effects of dispelling wind and draining dampness and dispersing swelling and removing toxin; the dioscorea nipponica makino has effects of activating blood and freeing meridians; the zaocys dhumnade has effects of dispelling wind, freeing meridians and relieving spasm; the eriocaulon buergerianum has effects of clearing heat and calming liver and removing nebula to promote eyesight; and the radix glycyrrhizae has effects of tonifying spleen and boosting qi. The raw material medicines are combined and the traditional Chinese medicine composition has effects of fortifying spleen and calming liver, and extinguishing wind and relieving spasm.